Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Presentation / Abstract • Phase 3presentation Fri, Oct 2, 2026, 4:30 PM EDT
Company profile
Mineralys Therapeutics, Inc.
Pipeline1 asset
- lorundrostatMLS-101 / Aldosterone synthase (CYP11B2) / Small molecule / Cardio-Renal-Metabolic SyndromeUncontrolled and treatment-resistant hypertensionPhase 3CompletedGlobalObstructive Sleep Apnea (OSA) and HypertensionPhase 2OngoingGlobalChronic Kidney Disease (CKD)Phase 2OngoingGlobal
Latest news24 items
All newsMineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Presentation / Abstract • Phase 2Oral presentation Thu, Oct 8, 2026, 11:45 AM ET
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Presentation / AbstractAHA Scientific Sessions late-breaking presentation Sun, Nov 8, 2026, 3:30 PM CT
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Presentation / Abstract • Phase 3Late-breaking poster presentation Sun, Jun 14, 2026, 10:00 AM EDT
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Presentation / Abstract • Phase 3Late-breaking poster presentation Sun, Jun 14, 2026, 9:00 AM CT
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Presentation / Abstract • Phase 3ESH 2026 presentation Sat, May 30, 2026, 11:15 AM EDT
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Presentation / Abstract • Phase 3Oral presentation Sat, May 30, 2026, 5:15 PM CEST